FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

0 Views· 07/10/23
OncLive® On Air
OncLive® On Air
0 Subscribers
0
In Drama

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

Show more

 0 Comments sort   Sort By


Up next